Recruiting

Targeted radiation therapy combined with hormone therapy for early-stage prostate cancer spread

Plain-English translation of NCT05209243 on ClinicalTrials.gov ↗ · Source last updated May 2023 · Translation generated July 2026 · How we translate trials

Read our Prostate Cancer research guide →

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This study tests whether adding stereotactic body radiation therapy (SBRT)—a precise, focused form of radiation that targets cancer spread sites—helps men with early-stage metastatic prostate cancer live longer and better. All participants receive standard hormone therapy and radiation to the main tumor, but half will also receive the specialized radiation treatment to any areas where cancer has spread to other parts of the body.

When prostate cancer spreads to just a few locations, doctors want to know if treating those specific spots with advanced radiation, along with hormone therapy, can control the disease better and improve survival compared to hormone therapy and standard radiation alone.

Do you qualify?

You likely qualify if…

you have been diagnosed with prostate cancer that has spread to a limited number of sites (3 or fewer on standard imaging, or 5 or fewer on advanced PET scans)
your prostate cancer is hormone-sensitive, meaning it still responds to hormone-blocking treatments
your cancer has spread to bones or lymph nodes, but not to organs like the liver or lungs
you have adequate kidney, liver, and bone marrow function based on blood tests
you have not previously received certain advanced hormone treatments like abiraterone or enzalutamide

You likely don't qualify if…

you have cancer that has spread to more than 3 sites on standard imaging or more than 5 on advanced PET scans
you are currently taking or have recently taken docetaxel or second-generation hormone medications
you have a serious heart condition or inflammatory bowel disease that would make radiation or hormone therapy unsafe
your cancer has spread to vital organs such as the liver or lungs
you are currently enrolled in another clinical trial

What participation looks like

You will first have imaging scans to confirm your cancer qualifies for the study. Then you'll be randomly assigned to one of two groups: one receives standard hormone therapy plus radiation to the main tumor, while the other receives the same standard care plus focused radiation to each area where cancer has spread. Both groups will have regular follow-up visits to monitor your health, blood work, and imaging scans over time to see how well the treatments work.

AI-generated summary from trial data · Jul 3, 2026 · Not medical advice

Trial locations(2 sites)

Spain

Hospital Universitario Ramón y Cajal, Madrid

Hospital Universitari i Politècnic La Fe, Valencia